Crystalys Therapeutics raises $130M to launch gout drug in US and Europe

San Diego‑based Crystalys Therapeutics announced a new $130 million Series B financing round. The capital will be used to advance its gout treatment, which already holds regulatory approval in Japan and China, into the United States and European markets.

The funding round underscores investor confidence in the company’s ability to commercialize the therapy outside Asia. Details of the investors were not disclosed in the brief report.

If successful, the expansion could provide a new option for gout patients in western markets and potentially increase the company’s revenue base.